President & Chief Executive Officer
Percival is the President & Chief Executive Officer of Plexium, the premier next-generation Targeted Protein Degradation company.
Percival joined Plexium in 2021 with extensive biopharmaceutical experience across various therapeutic areas, functions, and geographies. Prior to Plexium, Percival was the Chief Business Officer of Astellas Pharma Inc., where he spearheaded the execution of the company’s Corporate Strategic Plan and its efforts to enhance internal and external innovation. Percival’s earlier roles at Astellas included President of Astellas Pharma US, SVP International, and SVP Corporate Strategy, Business Development & Government Affairs. Before joining Astellas, Percival held increasingly senior commercial positions with the Roche Group in the United States and the United Kingdom. Percival earned a BS in Biological Sciences and Chemistry with Honors from Cornell University and an MBA from Yale University. In addition, Percival served as a Sloan Fellow for Innovation and Global Leadership at the MIT Sloan School of Management, where he was awarded an MS degree in Management. Percival is a board member of Americares, a health-focused relief and development organization that serves people affected by poverty or disaster with life-changing medicine and health programs.
Chief Financial Officer
Mr. Mullennix joins Plexium as Chief Financial Officer in May 2022.
Mr. Mullennix joins Plexium from ProSciento, Inc. where he served as Chief Financial Officer and played a critical role in advancing clinical methodologies for drugs and devices in the metabolic disease arena. Prior to ProSciento, Mr. Mullennix was Chief Financial Officer and Chief Operating Officer of UroGen Pharma, Ltd (NYSE:URGN). During his tenure at UroGen, he helped the company build its management team and corporate infrastructure that successfully launched its first FDA-approved drug for urothelial cancer and progressed a pipeline of Uro-Oncology drug candidates. Before UroGen, Mr. Mullennix was Chief Financial Officer and Senior Vice President of Operations at SolarReserve, LLC, a solar energy technology company, where he supported the company’s global expansion and oversaw multiple corporate and project financings. Prior to SolarReserve, he served as a Managing Director at US Renewables Group, a private equity investment fund with more than $750 million of assets under management. Mr. Mullennix has been directly involved in $3.3 billion of public, private, equity, debt and M&A transactions. He earned his MBA from the Anderson School at University of California Los Angeles and BA in Economic Geography from Dartmouth College.
Simon Bailey, Ph.D., MBA
Executive Vice President, Drug Discovery
The Head of Drug Discovery at Plexium, Simon oversees the company’s efforts to identify novel protein degrader drugs that address significant unmet medical needs.
Simon joined Plexium in 2019, bringing more than 25 years of experience in medicinal chemistry and small molecule drug discovery leadership. From 1995-2015, Simon held positions of increasing responsibility at Pfizer, including leading the Diabetes and Oncology Medicinal Chemistry Departments. Subsequently, Simon was the Head of Research and Global Pipeline Leader for Intercept Pharmaceuticals. There, he led the company’s programs from inception to Phase 2 in the area of fibrotic liver disease. Simon holds a Ph.D. and was the Hibbert Prize winner in synthetic organic chemistry from the University of Manchester. He completed postdoctoral studies under Prof. Leo Paquette at the Ohio State University and obtained an MBA from the University of California, San Diego. Simon is a 2021 recipient of the American Chemical Society’s Hero of Chemistry award for his role in the discovery of Lorbrena™.
Executive Vice President, Corporate Business Development
Kevin is the Executive Vice President of Corporate Development for Plexium.
He leads corporate strategy and is responsible for establishing external partnerships, managing strategic alliances, and supporting corporate financing initiatives. With over 30 years of industry experience, Kevin joined Plexium after working with large biotechnology companies, such as Agouron Pharmaceuticals and Gilead, and venture-backed start-ups, such as Achillion Pharmaceuticals and eFFECTOR Therapeutics. Prior to joining Plexium, Kevin was the Vice President of Corporate Development for the California Institute for Biomedical Research. He began his business development career at Agouron Pharmaceuticals and has significant experience across strategic partnerships, in-licensing, out-licensing, and M&A. Kevin graduated from Missouri State University with a degree in biology.
Peggy Thompson, Ph.D.
Vice President, Biology
Peggy is the Vice President of Biology, leading the targeted protein degradation drug discovery efforts at Plexium.
Peggy joined Plexium in 2020 with more than 20 years of experience in drug discovery and development in the biotechnology industry. Prior to Plexium, she was a co-founder and Executive Director of Biology at eFFECTOR Therapeutics, where she established their technology platform for targeting dysregulated mRNA translation for supporting oncology drug development. She also led their eIF4A program (Zotatifin, Phase II) from concept to clinical development in solid tumor malignancies. Before that, Peggy served as the Director of Biology at Anadys Pharmaceuticals, Inc., where she held positions of increasing responsibility, including leading the drug discovery biology efforts and supporting the development of Setrobuvir until the acquisition by Roche Pharmaceuticals. Prior to Anadys, Peggy held positions at Biopraxis and the National Institutes of Health. She was an NIH postdoctoral fellow in Biophysics at the University of California, Berkeley, and completed her Ph.D. in Chemistry from the University of California, San Diego. She received her B.S. with Highest Distinction in Biochemistry from Washington State University.
Yi Zhang, Ph.D.
Vice President, Engineering
As Vice President of Engineering, Yi directs the screening platform development for Plexium.
Yi joined Plexium in 2018, with more than 20 years of experience in instrument, bio-instrument, device, and assay design & development. Prior to Plexium, he was the Director of Engineering for Omniome, Inc. (now PacBio), a San Diego-based next-generation sequencing technology company. Yi spent the majority of his career at Celula, Inc. As the Director of Engineering and Assay Integration, he led a multidisciplinary team, including engineers and biologists, to develop multiple bio-instruments and assays for Non-Invasive Prenatal Test (NIPT) and fetal cell program. Yi began his career in the optical data storage field, developed 2-photon 3D optical data-storage technology. He earned a bachelor’s degree in Optical Engineering from Tsinghua University and graduated with a Ph.D. in Engineering.
Phyllis Balan, MBA
Vice President, Human Resources
Phyllis is the Vice President of Human Resources for Plexium.
Her responsibilities include managing people operations and overseeing organization effectiveness. Phyllis joined Plexium in March 2021, bringing over 20 years of experience in all aspects of human resources. Her skills and experience include talent management, talent acquisition, total rewards, and organizational development. Phyllis has held Human Resources leadership positions at AnaptysBio, Sotera Wireless, and Biogen. Prior to that, she held positions of increased responsibility in the technology industry. Phyllis received a Bachelor of Science and a Master of Business Administration from Michigan State University and an MA from San Diego State University in Educational Technology.
Board of Directors
President & CEO, Plexium
Partner, Lux Capital
Managing Partner, Pivotal Bioventure Partners
Managing Partner, The Column Group
Partner, TCG X
Managing Director at BVF Partners L.P.